SAN FRANCISCO -- Herculean efforts by scientists and physicians around the world have resulted more than 50 experimental COVID-19 vaccines currently in global clinical trials. The focus in the U.S.

AstraZeneca and Oxford University announced on Monday that they had developed a new Covid-19 vaccine with an efficacy rate of 70 to 90 percent. Trials indicated the vaccine could prevent 70 percent of ...

Nov 9 (Reuters) - An AstraZeneca (AZN.L), opens new tab executive said he felt encouraged by "incredibly promising" COVID-19 vaccine trial data unveiled by Pfizer and its German partner BioNTech, ...

WASHINGTON, DC: U.S. President Donald Trump shakes hands with Pfizer CEO Albert Bourla in the Oval Office of the White House as he announces a deal with Pfizer to lower drug prices on September 30, ...

Nov 23 (Reuters) - AstraZeneca (AZN.L), opens new tab said on Monday its vaccine for the novel coronavirus could be around 90% effective without any serious side effects, giving the world another ...

LONDON (Reuters) -Wall Street is looking to U.S. drugmaker Eli Lilly and Anglo-Swedish rival AstraZeneca as the potential next in line after Pfizer struck a deal with Donald Trump's administration to ...